Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases.

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

www.nurixtx.com →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

News

Bragar Eagel & Squire, P.C. Urges Ostin and NuScale Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff Deadlines

Swiss gold exports fall to their lowest level since the tariff shock of August 2025

VBR: Another March Selloff Makes For Another Small-Cap Value Buying Opportunity

Signet Jewelers: Resilient Earnings Make Shares Attractive

Should Investors Buy Knight-Swift Stock Post Dividend Hike?

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm

Indiana American Water Announces More Than $246 Million Invested in 2025 Statewide Infrastructure Upgrades

Mount Logan Capital Inc. (MLCI) Q4 2025 Earnings Call Transcript

RATIONAL Aktiengesellschaft (RATIY) Q4 2025 Press Conference Call Transcript

Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play

Earnings Tailwinds v. Supply Headwinds: MU's Complicated Path Ahead

Tencent Q4 Earnings Beat Estimates, Revenues Increase Y/Y

UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V.

Why Tapestry Might Outpace Nike In 2026

Marine Corps Enlisted Leaders Visit HII's Ingalls Shipbuilding to Advance Veteran-to-Shipbuilding Workforce Pipeline

Tesla has ‘lots of irons in the fire' — but its stock is unusually calm

Alibaba AI Adoption Drives 36% Cloud Growth

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kyndryl Holdings and Masonite International and Encourages Investors to Contact the Firm

Netflix Retreats: The Streaming Giant Faces Its Toughest Balancing Act Yet

How To Know Which Consumer Stocks the Iran War Has Put Most at Risk

About